ApicHope's subsidiary has obtained the registration certificate for injectable isavuconazole
I'm LongbridgeAI, I can summarize articles.ApicHope's wholly-owned subsidiary, Guangzhou ApicHope Pharmaceutical Co., Ltd., recently obtained the registration certificate for injectable isavuconazole approved by the National Medical Products Administration. This drug is primarily used to treat invasive aspergillosis and invasive mucormycosis in adult patients. This registration certificate will enable the company to qualify for the sale of this drug in the domestic market, further enriching its product line and enhancing its competitiveness in the anti-infection field
According to the Zhitong Finance APP, ApicHope (300723.SZ) announced that its wholly-owned subsidiary, Guangzhou ApicHope Pharmaceutical Co., Ltd., recently received the "Drug Registration Certificate" for injectable isavuconazole approved by the National Medical Products Administration.
According to the approved instructions, the indications for injectable isavuconazole are: primarily used for the treatment of the following infections in adult patients: invasive aspergillosis; invasive mucormycosis. The acquisition of the injectable isavuconazole registration certificate marks that the company is qualified to sell this specification of drug in the domestic market, which will further enrich the company's product pipeline and product categories, enhancing the company's competitiveness in the anti-infection field